Li Nana, Liao Xiaoqin, Chen Ling, Wang Jianhua, Liu Mei, Zhang Hong
1Department of Respiratory Medicine, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China.
2Z-BioMed, Inc., Rockville, Maryland.
Microb Drug Resist. 2015 Jun;21(3):292-6. doi: 10.1089/mdr.2014.0094. Epub 2015 Jan 19.
A total of 92 Mycobacterium tuberculosis isolates were collected from patients with pulmonary tuberculosis (TB) in the Zunyi region between 2011 and 2012. Collected isolates were used to determine antibiotic susceptibility patterns against 13 anti-TB drugs: 4 first-line and 9 second-line (ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, para-aminosalicylic acid, amikacin, capreomycin, kanamycin, and prothionamide) drugs. Results showed that among 57 new cases of TB only 66.7% were susceptible to all four first-line anti-TB drugs and 64.9% were susceptible to fluoroquinolones and second-line injectables; 10.5% of new and 22.9% of previously treated cases were multidrug-resistant TB (MDR-TB); and 1.8% of new and 2.9% of previously treated cases were extensively drug-resistant TB (XDR-TB). In addition, 14.3% of MDR-TB cases (2 out of 14) were XDR-TB, which is higher than the average numbers in China (about 8%) and in the world (9.6%). This study confirms that primary transmission of drug-resistant TB, including MDR/XDR-TB, is a real threat to achieving effective control of drug-resistant TB in the Guizhou Province and indicates the necessity to determine antibiotic susceptibility patterns in patients with TB to improve treatment outcomes.
2011年至2012年期间，从遵义地区的肺结核患者中总共收集了92株结核分枝杆菌分离株。收集的分离株用于确定对13种抗结核药物的药敏模式：4种一线药物和9种二线药物（环丙沙星、加替沙星、左氧氟沙星、莫西沙星、对氨基水杨酸、阿米卡星、卷曲霉素、卡那霉素和丙硫异烟胺）。结果显示，在57例新的肺结核病例中，仅66.7%对所有四种一线抗结核药物敏感，64.9%对氟喹诺酮类和二线注射剂敏感；10.5%的新病例和22.9%的既往治疗病例为耐多药结核病（MDR-TB）；1.8%的新病例和2.9%的既往治疗病例为广泛耐药结核病（XDR-TB）。此外，14.3%的MDR-TB病例（14例中的2例）为XDR-TB，高于中国（约8%）和全球（9.6%）的平均水平。本研究证实，包括MDR/XDR-TB在内的耐药结核病的原发传播对贵州省有效控制耐药结核病构成了现实威胁，并表明有必要确定肺结核患者的药敏模式以改善治疗效果。
